Suzetrigine (JOURNAVX, Formerly VX-548) for Pain Hyperacusis (Noxacusis)?

starlight

Member
Author
Mar 10, 2025
1
Tinnitus Since
2022
Cause of Tinnitus
Acoustic Trauma & Infection
Has anyone tried Suzetrigine for pain hyperacusis or noxacusis? It is being distributed as JOURNAVX by Vertex Pharmaceuticals and was previously labeled VX-548 during clinical trials.

The FDA approved it on January 30, 2025. It targets moderate to severe pain by blocking pain signals in the peripheral nervous system. While it is designed for acute cases, clinical trials showed some efficacy for nerve damage, specifically in diabetic peripheral neuropathy.

IMG_4491.jpeg


Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
 

Log in or register to get the full forum benefits!

Register

Register on Tinnitus Talk for free!

Register Now